1. |
Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2018, 68(6): 394-424.
|
2. |
王维琼. 2016年中国恶性肿瘤发病和死亡分析. 临床医药文献电子杂志, 2017, 4(19): 3604.
|
3. |
Ajani JA, Bentrem DJ, Besh S, et al. Gastric cancer, version 2. 2013: featured updates to the NCCN Guidelines. J Natl Compr Canc Netw, 2013, 11(5): 531-546.
|
4. |
Das M. Neoadjuvant chemotherapy: survival benefit in gastric cancer. Lancet Oncol, 2017, 18(6): e307.
|
5. |
Hu Y, Hu D, Li W, et al. Neoadjuvant chemotherapy brings more survival benefits than postoperative chemotherapy for resectable gastric cancer: a meta-analysis of randomized controlled trials. J BUON, 2019, 24(1): 201-214.
|
6. |
Frei E 3rd. Clinical cancer research: an embattled species. Cancer, 1982, 50(10): 1979-1992.
|
7. |
Wilke H, Preusser P, Fink U, et al. Preoperative chemotherapy in locally advanced and nonresectable gastric cancer: a phase Ⅱ study with etoposide, doxorubicin, and cisplatin. J Clin Oncol, 1989, 7(9): 1318-1326.
|
8. |
Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med, 2006, 355(1): 11-20.
|
9. |
Ychou M, Boige V, Pignon JP, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase Ⅲ trial. J Clin Oncol, 2011, 29(13): 1715-1721.
|
10. |
Ajani JA, D'Amico TA, Almhanna K, et al. Gastric cancer, version 3. 2016, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw, 2016, 14(10): 1286-1312.
|
11. |
Schuhmacher C, Gretschel S, Lordick F, et al. Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954. J Clin Oncol, 2010, 28(35): 5210-5218.
|
12. |
Gabriel E, Attwood K, Narayanan S, et al. Does neoadjuvant/ perioperative chemotherapy improve overall survival for T2N0 gastric adenocarcinoma? J Surg Oncol, 2018, 117(4): 659-670.
|
13. |
杨娟, 燕速. 影响进展期胃癌新辅助化疗患者临床疗效的危险因素. 实用癌症杂志, 2017, 32(5): 770-772.
|
14. |
赵国杰, 张赟鑫, 王博, 等. 不同分化程度局部进展期胃癌新辅助化疗效果对比分析. 中国普外基础与临床杂志, 2015, 22(4): 464-467.
|
15. |
Terashima M, Iwasaki Y, Mizusawa J, et al. Randomized phase Ⅲ trialof gastrectomy with or without neoadjuvant S-1 plus cisplatin for type 4or large type 3 gastric cancer, the short-term safety and surgical results: Japan Clinical Oncology Group Study (JCOG0501). Gastric Cancer, 2019 Mar 2. doi: 10.1007/s10120-019-00941-z.
|
16. |
Kanaji S, Suzuki S, Matsuda Y, et al. Recent updates in perioperative chemotherapy and recurrence pattern of gastric cancer. Ann Gastroenterol Surg, 2018, 2(6): 400-405.
|
17. |
Tsuburaya A, Mizusawa J, Tanaka Y, et al. Neoadjuvant chemotherapy with S-1 and cisplatin followed by D2 gastrectomy with para-aortic lymph node dissection for gastric cancer with extensive lymph node metastasis. Br J Surg, 2014, 101(6): 653-660.
|
18. |
Kataoka K, Tokunaga M, Mizusawa J, et al. A randomized Phase II trial of systemic chemotherapy with and without trastuzumab followed by surgery in HER2-positive advanced gastric or esophagogastric junction adenocarcinoma with extensive lymph node metastasis: Japan Clinical Oncology Group study JCOG1301 (Trigger Study). Jpn J Clin Oncol, 2015, 45(11): 1082-1086.
|
19. |
Ito S, Sano T, Mizusawa J, et al. A phase Ⅱ study of preoperative chemotherapy with docetaxel, cisplatin, and S-1 followed by gastrectomy with D2 plus para-aortic lymph node dissection for gastric cancer with extensive lymph node metastasis: JCOG1002. Gastric Cancer, 2017, 20(2): 322-331.
|
20. |
Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2014 (ver. 4). Gastric Cancer, 2017, 20(1): 1-19.
|
21. |
Al-Batran S E, Homann N, Schmalenberg H, et al. Perioperative chemotherapy with docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) versus epirubicin, cisplatin, and fluorouracil or capecitabine (ECF/ECX) for resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma (FLOT4-AIO): A multicenter, randomized phase 3 trial. J Clin Oncol, 2017, 35(15_suppl): 4004.
|
22. |
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines*): gastric cancer (Version 2. 2018). (2018-05-22)[2018-05-27]. www.nccn.org.
|
23. |
Bose K, Franck C, Müller MN, et al. Perioperative therapy of oesophagogastric adenocarcinoma: mainstay and future directions. Gastroenterol Res Pract, 2017, 2017: 5651903.
|
24. |
Alderson D, Cunningham D, Nankivell M, et al. Neoadjuvant cisplatin and fluorouracil versus epirubicin, cisplatin, and capecitabine followed by resection in patients with oesophageal adenocarcinoma (UK MRC OE05): an open-label, randomised phase 3 trial. Lancet Oncol, 2017, 18(9): 1249-1260.
|
25. |
Smyth EC, Verheij M, Allum W, et al. Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 2016, 27(suppl 5): v38-v49.
|
26. |
Fukagawa T, Katai H, Mizusawa J, et al. A prospective multi-institutional validity study to evaluate the accuracy of clinical diagnosis of pathological stage Ⅲ gastric cancer (JCOG1302A). Gastric Cancer, 2018, 21(1): 68-73.
|
27. |
Sasaki K, Onodera S, Otsuka K, et al. Validity of neoadjuvant chemotherapy with docetaxel, cisplatin, and S-1 for resectable locally advanced gastric cancer. Med Oncol, 2017, 34(8): 139.
|
28. |
Yoshikawa T, Morita S, Tanabe K, et al. Survival results of a randomised two-by-two factorial phase Ⅱ trial comparing neoadjuvant chemotherapy with two and four courses of S-1 plus cisplatin (SC) and paclitaxel plus cisplatin (PC) followed by D2 gastrectomy for resectable advanced gastric cancer. Eur J Cancer, 2016, 62: 103-111.
|
29. |
Aoyama T, Nishikawa K, Fujitani K, et al. Early results of a randomized two-by-two factorial phase Ⅱ trial comparing neoadjuvant chemotherapy with two and four courses of cisplatin/S-1 and docetaxel/cisplatin/S-1 as neoadjuvant chemotherapy for locally advanced gastric cancer. Ann Oncol, 2017, 28(8): 1876-1881.
|
30. |
Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet, 2010, 376(9742): 687-697.
|
31. |
Hofheinz R, Hegewischbecker S, Thusspatience PC, et al. HER-FLOT: Trastuzumab in combination with FLOT as perioperative treatment for patients with HER2-positive locally advanced esophagogastric adenocarcinoma: A phase Ⅱ trial of the AIO Gastric Cancer Study Group. J Clin Oncol, 2014.
|
32. |
Gong J, Liu T, Fan Q, et al. Optimal regimen of trastuzumab in combination with oxaliplatin/ capecitabine in first-line treatment of HER2-positive advanced gastric cancer (CGOG1001): a multicenter, phase Ⅱ trial. BMC Cancer, 2016, 16: 68.
|
33. |
Cunningham D, Stenning SP, Smyth EC, et al. Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2–3 trial. Lancet Oncol, 2017, 18(3): 357-370.
|
34. |
Shitara K, Kadowaki S, Nishina T, et al. Safety, pharmacokinetic, and clinical activity profiles of ramucirumab in combination with three platinum/fluoropyrimidine doublets in Japanese patients with chemotherapy-naïve metastatic gastric/gastroesophageal junction cancer. Gastric Cancer, 2018, 21(1): 106-113.
|
35. |
Roviello G, Ravelli A, Polom K, et al. Apatinib: A novel receptor tyrosine kinase inhibitor for the treatment of gastric cancer. Cancer Lett, 2016, 372(2): 187-191.
|
36. |
Lorenzen S, Riera Knorrenschild J, Haag GM, et al. Lapatinib versus lapatinib plus capecitabine as second-line treatment in human epidermalgrowth factor receptor 2-amplified metastatic gastro-oesophageal cancer: a randomised phase Ⅱ trial of the Arbeitsgemeinschaft Internistische Onkologie. Eur J Cancer, 2015, 51(5): 569-576.
|
37. |
Lordick F, Kang YK, Chung HC, et al. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. Lancet Oncol, 2013, 14(6): 490-499.
|
38. |
Tebbutt NC, Price TJ, Ferraro DA, et al. Panitumumab added to docetaxel, cisplatin and fluoropyrimidine in oesophagogastric cancer: ATTAX3 phase Ⅱ trial. Br J Cancer, 2016, 114(5): 505-509.
|
39. |
Kondoh C, Kadowaki S, Komori A, et al. Salvage chemotherapy with the combination of oxaliplatin, leucovorin, and 5-fluorouracil in advanced gastric cancer refractory or intolerant to fluoropyrimidines, platinum, taxanes, and irinotecan. Gastric Cancer, 2018, 21(6): 1050-1057.
|
40. |
Fuchs CS, Doi T, Jang RW, et al. Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction vancer: phase 2 clinical KEYNOTE-059 trial. JAMA Oncol, 2018, 4(5): e180013.
|
41. |
Apicella M, Corso S, Giordano S. Targeted therapies for gastric cancer: failures and hopes from clinical trials. Oncotarget, 2017, 8(34): 57654-57669.
|
42. |
刘丹, 伍兵. 胃癌影像学的研究进展. 中国普外基础与临床杂志, 2018, 25(9): 1124-1129.
|
43. |
Yoshikawa T, Tanabe K, Nishikawa K, et al. Accuracy of CT staging of locally advanced gastric cancer after neoadjuvant chemotherapy: cohort evaluation within a randomized phase Ⅱ study. Ann Surg Oncol, 2014, 21(Suppl 3): S385-S389.
|
44. |
Guo T, Yao F, Yang AM, et al. Endoscopic ultrasound in restaging and predicting pathological response for advanced gastric cancer patients after neoadjuvant chemotherapy. Asia Pac J Clin Oncol, 2014, 10(2): e28-e32.
|
45. |
Yonemura Y, Kinoshita K, Fujimura T, et al. Correlation of the histological effects and survival after neoadjuvant chemotherapy on gastric cancer patients. Hepatogastroenterology, 1996, 43(11): 1260-1272.
|
46. |
Becker K, Mueller JD, Schulmacher C, et al. Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer, 2003, 98(7): 1521-1530.
|
47. |
Redondo-Cerezo E, Martínez-Cara JG, Jiménez-Rosales R, et al. Endoscopic ultrasound in gastric cancer staging before and after neoadjuvant chemotherapy. A comparison with PET-CT in a clinical series. United European Gastroenterol J, 2017, 5(5): 641-647.
|
48. |
Marcus CD, Ladam-Marcus V, Cucu C, et al. Imaging techniques to evaluate the response to treatment in oncology: current standards and perspectives. Crit Rev Oncol Hematol, 2009, 72(3): 217-238.
|
49. |
Lee DH, Kim SH, Joo I, et al. CT Perfusion evaluation of gastric cancer: correlation with histologic type. Eur Radiol, 2018, 28(2): 487-495.
|
50. |
Park S, Ha S, Kwon HW, et al. Prospective evaluation of changes in tumor size and tumor metabolism in patients with advanced gastric cancer undergoing chemotherapy: association and clinical implication. J Nucl Med, 2017, 58(6): 899-904.
|
51. |
Cheng J, Wang Y, Zhang CF, et al. Chemotherapy response evaluation in a mouse model of gastric cancer using intravoxel incoherent motion diffusion-weighted MRI and histopathology. World J Gastroenterol, 2017, 23(11): 1990-2001.
|
52. |
Kruk-Bachonko J, Krupski W, Czechowski M, et al. Perfusion CT—A novel quantitative and qualitative imaging biomarker in gastric cancer. Eur J Radiol, 2017, 95: 399-408.
|
53. |
Liang JX, Bi XJ, Li XM, et al. Evaluation of multislice spiral computed tomography perfusion imaging for the efficacy of preoperative concurrent chemoradiotherapy in middle-aged and elderly patients with locally advanced gastric cancer. Med Sci Monit, 2018, 24: 235-245.
|
54. |
Djuric-Stefanovic A, Micev M, Stojanovic-Rundic S, et al. Absolute CT perfusion parameter values after the neoadjuvant chemoradiotherapy of the squamous cell esophageal carcinoma correlate with the histopathologic tumor regression grade. Eur J Radiol, 2015, 84(12): 2477-2484.
|
55. |
Ott K, Weber WA, Lordick F, et al. Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction. J Clin Oncol, 2006, 24(29): 4692-4698.
|
56. |
Malibari N, Hickeson M, Lisbona R. PET/computed tomography in the diagnosis and staging of gastric cancers. PET Clin, 2015, 10(3): 311-326.
|
57. |
Giganti F, Tang L, Baba H. Gastric cancer and imaging biomarkers: Part 1—a critical review of DW-MRI and CE-MDCT findings. Eur Radiol, 2019, 29(4): 1743-1753.
|
58. |
De Cobelli F, Giganti F, Orsenigo E, et al. Apparent diffusion coefficient modifications in assessing gastro-oesophageal cancer response to neoadjuvant treatment: comparison with tumour regression grade at histology. Eur Radiol, 2013, 23(8): 2165-2174.
|